PURPOSE: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumour scintigraphy and radionuclide therapy. The kidney is the most important critical organ during such therapy owing to the reabsorption and retention of radiolabelled peptides. The aim of this study was to investigate in a rat model both the localisation and the mechanism of renal uptake after intravenous injection of radiolabelled somatostatin analogues. The multi-ligand megalin/cubilin receptor complex, responsible for reabsorption of many peptides and proteins in the kidney, is an interesting candidate for renal endocytosis of these peptide analogues. METHODS: For localisation studies, ex vivo autoradiography and micro-autoradiography of rat kidneys were performed 1-24 h after injection of radiolabelled somatostatin analogues and compared with the renal anti-megalin immunohistochemical staining pattern. To confirm a role of megalin in the mechanism of renal retention of [111In-DTPA]octreotide, the effects of three inhibitory substances were explored in rats. RESULTS: Renal ex vivo autoradiography showed high cortical radioactivity and lower radioactivity in the outer medulla. The distribution of cortical radioactivity was inhomogeneous. Micro-autoradiography indicated that radioactivity was only retained in the proximal tubules. The anti-megalin immunohistochemical staining pattern showed a strong similarity with the renal [111In-DTPA]octreotide ex vivo autoradiograms. Biodistribution studies showed that co-injection of positively charged D-lysine reduced renal uptake to 60% of control. Sodium maleate reduced renal [111In-DTPA]octreotide uptake to 15% of control. Finally, cisplatin pre-treatment of rats reduced kidney uptake to 70% of control. CONCLUSION: Renal retention of [111In-DTPA]octreotide is confined to proximal tubules in the rat kidney, in which megalin-mediated endocytosis may play an important part.
PURPOSE: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumour scintigraphy and radionuclide therapy. The kidney is the most important critical organ during such therapy owing to the reabsorption and retention of radiolabelled peptides. The aim of this study was to investigate in a rat model both the localisation and the mechanism of renal uptake after intravenous injection of radiolabelled somatostatin analogues. The multi-ligand megalin/cubilin receptor complex, responsible for reabsorption of many peptides and proteins in the kidney, is an interesting candidate for renal endocytosis of these peptide analogues. METHODS: For localisation studies, ex vivo autoradiography and micro-autoradiography of rat kidneys were performed 1-24 h after injection of radiolabelled somatostatin analogues and compared with the renal anti-megalin immunohistochemical staining pattern. To confirm a role of megalin in the mechanism of renal retention of [111In-DTPA]octreotide, the effects of three inhibitory substances were explored in rats. RESULTS: Renal ex vivo autoradiography showed high cortical radioactivity and lower radioactivity in the outer medulla. The distribution of cortical radioactivity was inhomogeneous. Micro-autoradiography indicated that radioactivity was only retained in the proximal tubules. The anti-megalin immunohistochemical staining pattern showed a strong similarity with the renal [111In-DTPA]octreotide ex vivo autoradiograms. Biodistribution studies showed that co-injection of positively charged D-lysine reduced renal uptake to 60% of control. Sodium maleate reduced renal [111In-DTPA]octreotide uptake to 15% of control. Finally, cisplatin pre-treatment of rats reduced kidney uptake to 70% of control. CONCLUSION: Renal retention of [111In-DTPA]octreotide is confined to proximal tubules in the rat kidney, in which megalin-mediated endocytosis may play an important part.
Authors: M de Jong; E J Rolleman; B F Bernard; T J Visser; W H Bakker; W A Breeman; E P Krenning Journal: J Nucl Med Date: 1996-08 Impact factor: 10.057
Authors: T M Behr; R M Sharkey; M E Juweid; R D Blumenthal; R M Dunn; G L Griffiths; H J Bair; F G Wolf; W S Becker; D M Goldenberg Journal: Cancer Res Date: 1995-09-01 Impact factor: 12.701
Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi Journal: Eur J Nucl Med Date: 1993-08
Authors: W H Bakker; E P Krenning; J C Reubi; W A Breeman; B Setyono-Han; M de Jong; P P Kooij; C Bruns; P M van Hagen; P Marbach Journal: Life Sci Date: 1991 Impact factor: 5.037
Authors: Leo J Hofland; Steven W J Lamberts; P Martin van Hagen; Jean-Claude Reubi; James Schaeffer; Marlijn Waaijers; Peter M van Koetsveld; Ananth Srinivasan; Eric P Krenning; Wout A P Breeman Journal: J Nucl Med Date: 2003-08 Impact factor: 10.057
Authors: Edgar J Rolleman; Roelf Valkema; Marleen Melis; Marion de Jong; Eric P Krenning; Theo J Visser; Edgar J Rolleman Journal: Eur J Nucl Med Mol Imaging Date: 2006-06 Impact factor: 9.236
Authors: Torun Ekblad; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsén; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: Eur J Nucl Med Mol Imaging Date: 2008-07-02 Impact factor: 9.236
Authors: Azhar Pasha; Mai Lin; Gyula Tircsó; Cynthia L Rostollan; Mark Woods; Garry E Kiefer; A Dean Sherry; Xiankai Sun Journal: J Biol Inorg Chem Date: 2008-12-13 Impact factor: 3.358
Authors: Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2009-12 Impact factor: 9.236